WallStSmart

RadNet Inc (RDNT)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 2084% more annual revenue ($44.56B vs $2.04B). TMO leads profitability with a 15.0% profit margin vs -0.9%. RDNT appears more attractively valued with a PEG of 0.96. TMO earns a higher WallStSmart Score of 59/100 (C).

RDNT

Buy

54

out of 100

Grade: C-

Growth: 8.0Profit: 4.0Value: 6.7Quality: 4.8
Piotroski: 2/9Altman Z: 1.19

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for RDNT.

TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RDNT2 strengths · Avg: 9.0/10
EPS GrowthGrowth
75.0%10/10

Earnings expanding 75.0% YoY

PEG RatioValuation
0.968/10

Growing faster than its price suggests

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

RDNT4 concerns · Avg: 2.5/10
Return on EquityProfitability
1.4%3/10

ROE of 1.4% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-230.86M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : RDNT

The strongest argument for RDNT centers on EPS Growth, PEG Ratio. Revenue growth of 14.8% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : RDNT

The primary concerns for RDNT are Return on Equity, Piotroski F-Score, Free Cash Flow.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

RDNT profiles as a turnaround stock while TMO is a value play — different risk/reward profiles.

RDNT carries more volatility with a beta of 1.46 — expect wider price swings.

RDNT is growing revenue faster at 14.8% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (59/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

RadNet Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

RadNet, Inc., provides outpatient imaging services in the United States. The company is headquartered in Los Angeles, California.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?